News Releases
Dec 07, 2020
Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of Chronic Rhinosinusitis With and Without Nasal Polyps
Additional Formats
Nov 12, 2020
Lyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual London Healthcare Conference
Additional Formats
Nov 10, 2020
Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Additional Formats
Oct 28, 2020
Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors
Additional Formats
Sep 10, 2020
Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis
Additional Formats
Sep 03, 2020
Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis
Additional Formats
Aug 05, 2020
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Additional Formats
Aug 04, 2020
Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference
Additional Formats
Aug 04, 2020
Lyra Therapeutics Announces Pamela Nelson as Senior Vice President of Regulatory Affairs
Additional Formats
Jul 30, 2020
Lyra Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference
Additional Formats
Displaying 1 - 10 of 20